Similar articles

• Targeted therapies in colorectal carcinoma: addressing toxicities associated with EGFR inhibitors.

  Biedrzycki BA. Biedrzycki BA. ONS Connect. 2007;22(8 Suppl):33-4. ONS Connect. 2007. PMID: 17824555 No abstract available.
• Integrating targeted agents into therapeutic regimens for patients with resectable colorectal cancer.

  Marshall JL. Marshall JL. Clin Colorectal Cancer. 2008 Dec;7 Suppl 2:S63-6. doi: 10.3816/CCC.2008.s.010. Clin Colorectal Cancer. 2008. PMID: 19064409 Review.
• [A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].

  Kawakami H, Satoh T, Nakagawa K. Kawakami H, et al. Nihon Rinsho. 2011 Apr;69 Suppl 3:439-45. Nihon Rinsho. 2011. PMID: 22214001 Review. Japanese. No abstract available.
• Targeted therapies in lung cancer: a tribute to advancements in clinical research.

  McGee L. McGee L. ONS Connect. 2007;22(8 Suppl):27-8. ONS Connect. 2007. PMID: 17824552 Review. No abstract available.
• Targeted therapies: aiming for the bull's-eye.

  Gaguski ME. Gaguski ME. ONS Connect. 2007 Jul;22(7):8-12. ONS Connect. 2007. PMID: 17694778 No abstract available.